Malaria
865
22
39
677
Key Insights
Highlights
Success Rate
96% trial completion (above average)
Published Results
135 trials with published results (16%)
Research Maturity
677 completed trials (78% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
3.5%
30 terminated out of 865 trials
95.8%
+9.2% vs benchmark
27%
233 trials in Phase 3/4
20%
135 of 677 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 677 completed trials
Clinical Trials (865)
Evaluation, Treatment and Monitoring of Patients With a Known or Suspected Parasitic Infection
Laboratory Evaluation of Pregnancy Malaria Vaccine Candidates/In-vitro Testing of Pregnancy Malaria Vaccine Candidates
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
L9LS MAb in Malian Infants
Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays
Safety, Tolerability, Pharmacokinetics, and Mosquitocidal Activity of Lotilaner in Healthy Participants in Mali.
Malaria Rapid Diagnostic Tests (RDTs) in Pregnancy: Detection of Placental Malaria
Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1)
Validation of a CDSA Strategy to Reduce Antibiotic Prescription in Senegal
Intermittent Preventive Treatment of Malaria in School-age Children to Decrease Community Transmission
Perennial Malaria Chemoprevention (PMC) in Cameroon
Perennial Malaria Chemoprevention (PMC) in Côte d'Ivoire
OPTIMAL LEAP: Optimizing Dihydroartemisinin-Piperaquine IPTsc Intervals to Advance Learning, Executive Function, Attendance, and Antimalarial Resistance Surveillance in Kenyan Schoolchildren
Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge
A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria
Evaluation of a Comprehensive School Health Programme in Zambia
Host and Parasite Factors That Influence Susceptibility to Malaria Infection and Disease During Pregnancy and Early Childhood in Ouelessebougou and Bamako, Mali
First-in-Human PfSPZ-LARC2 Vaccination/CHMI
A Study of Oral E1018 in Healthy Adult Participants
A Study of the Plasmodium Falciparum Malaria Vaccine Candidate Pfs48/45 in Matrix-M Adjuvant in the UK